Pharmacological comparison of the statins

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 9, 2003, Pages 605-611

  Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Clinical efficacy; Drug interactions; Equieffective doses; Pharmacokinetics; Statins

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 INHIBITOR; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MIBEFRADIL; NELFINAVIR; PRAVASTATIN; RAVUCONAZOLE; RIFAMPICIN; SIMVASTATIN; VERAPAMIL;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG SAFETY; GRAPE JUICE; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; REVIEW; RHABDOMYOLYSIS;

EID: 0141426821     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297156     Document Type: Review

References (39)

1. Backman, J. T., Kyrklund, C., Neuvonen, M. et al., Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685 (2002)
2. Brown, W. V., Bays, H. E., Hassman, D. R. et al., Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am. Heart J. 144, 1036 (2002)
3. Chong, P. H., Seeger, J. D., Franklin, C., Clinically relevant differences between the statins: implication for therapeutic selection. Am. J. Med. 111, 390 (2001)
4. Corsini, A., Bellosta, S., Baetta, R. et al., New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84, 413 (1999)
5. DeWilde, S., Carey, I. M., Brenner, S. A., Richardo, N., Hilton, S. R., Cook, D. G., Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 89, 417 (2003)
6. Downs, J. R., Clearfield, M., Weis, S. et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615 (1998)
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA 285, 2486 (2001)
8. Grundy, S. M., Cleeman, J. I., Rifkind, B. M. et al., Cholesterol lowering in the elderly population. Coordinating Committee on the National Cholesterol Education Program. Arch. Intern. Med. 159, 1670 (1999)
9. Harder, S., Mohr, O., Klepzig, H., Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic. Int. J. Clin. Pharmacol. Ther. 39, 534 (2001)
10. Heart Protection Study Collaborative Group, MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7 (2002)
11. Hebert, P. R, Gaziano, J. M., Chan, K. S. et al., Cholesterol lowering with statin drugs risk of stroke, and total mortality. An overview of randomized trials. JAMA 278, 313 (1997)
12. Herd, A., Ballantyne, C., Farmer J. et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am. J. Cardiol. 80, 278 (1997)
13. Hsiang, B., Zhu, Y., Wang, Z. et al., A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161 (1999)
14. Illingworth, D. R., Tobert, J. A., A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin. Ther. 16, 366 (1994)
15. Jones, P. H., Comparing HMG-CoA reductase inhibitors. Clin. Cardiol. 26 (Suppl. 1), I15 (2003)
16. Jones, P., Kafonek, S., Laurora, I. et al. for the CURVES Investigators, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am. J. Cardiol. 81, 582 (1998)
17. Kosoglou, T., Meyer, I. Veltre E. P. et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br. J. Clin. Pharmacol. 54, 309 (2002)
18. LaRosa, J. C., He, J., Vupputuri, S., Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 282, 2340 (1999)
19. Lennernäs, H., Fager, G., Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32, 403 (1997)
20. Lipid Study Group Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359, 1379 (2002)
21. Long-term Intervention with Pravastatin Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349 (1998)
22. Maron, D. J., Fazio, S., Linton, M. R. F., Curient perspectives on statins. Circulation 101, 207 (2000)
23. Pedersen, T. R. J. for the Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383 (1994)
24. Prueksaritanont, T., Zhao, J. J., Ma, B. et al., Mechanistic studies on metabolic interaction between gemfibrozil and statins. J. Pharmacol. Exper. Ther. 301, 1042 (2002)
25. Reinoso, R. F., Navarro, A. S., Garcia, M. J. et al., Pharmacokinetic interactions of statins, Methods Find. Exp. Clin. Pharmacol. 23, 541 (2001)
26. Roberts, W. C., The rule of 5 and the rule of 7 in lipid lowering by statin drugs. Am. J. Cardiol. 80, 106 (1997)
27. Sacks, F., Pfeffer, M., Moye, L. et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001 (1996)
28. Schneck, D. W., Knopp, R. H., Ballantyne, C. M. et al., Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol. 91, 33 (2003)
29. Shephard, J., Blauw, G. J., Murphy, M. B. et al., Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623 (2002)
30. Shephard, J., Cobbe, S., Ford, I. et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med. 333, 1301 (1995)
31. Simes, J., Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359, 1379 (2002)
32. Simon, S. R., Gurwitz, J. H., Drug therapy in the elderly: Improving quality and access. Clin. Pharmacol. Ther. 73, 387 (2003)
33. Stein, E. A., Davidson, M. H., Dobs, A. S. et al., Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am. J. Cardiol. 82, 311 (1998)
34. Stein, E. A., Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Drugs 56 (Suppl. 1), 25 (1998)
35. Sudhop, T., Lutjohann, D., Kodal, A. et al., Inhibition of intestinal Cholesterol absorption by ezetimibe in humans. Circulation 106, 1943 (2002)
36. Thompson, P. D., Clarkson, P., Karas, R. H., Statin-associated myopathy. JAMA 289, 1681 (2003)
37. Veillard, N. R., Mach, F., Statins: the new aspirin? Cell. Mol. Life Sci. 59, 1771 (2002)
38. Waldman, A., Kritharides, L. Z, The pleiotropic effects of HMG-CoA reductase inhibitors. Their role in osteoporosis and dementia. Drugs 63, 139 (2003)
39. Williams, D., Feely, J., Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 41, 343 (2002)